Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInternational Biotechnology Trust plc

International Biotechnology Trust plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1020.0 GBX 5.00 ( 0.49%)
Last update at 2026-10-27T16:35:00Z
VOLUME
175689
Market Cap
307.86M

Momentum Score

…

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1010.00
Low
1045.00
High
52 Week Price Range
498.71
Low
998.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1015.00
Dividend Yield
3.32%
Revenue TTM
5.25M
Revenue Per Share
0.15
Gross Profit TTM
5.25M
Debt / Equity
0.12
ROE
-0.44%
Net Debt
14.63M
ROCE
-0.01%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -1.14M 39.01M 6.93M -22.32M 28.05M
Net income -1.17M 38.88M 6.81M -22.47M 27.89M
Selling general administrative 0.97M 1.13M 1.56M 1.22M 1.07M
Gross profit 14.38M 40.14M 8.49M -21.10M 29.12M
Ebit - 37.90M - -17.28M 28.20M
Ebitda -0.02M 39.55M 6.93M -21.66M 28.05M
Depreciation and amortization - 1.66M - - -
Operating income -0.02M 39.55M 6.93M -21.66M 28.05M
Other operating expenses 18.71M 3.33M 1.56M 1.22M 1.07M
Interest expense 1.94M 2.20M 1.24M 0.66M 0.22M
Tax provision 0.03M 0.14M 0.12M 0.15M 0.16M
Interest income 0.23M 0.22M 0.02M 0.00M 0.00M
Net interest income -1.71M -1.98M -1.22M -0.66M -0.22M
Income tax expense 0.03M 0.14M 0.12M 0.15M 0.16M
Total revenue 18.69M 42.34M 8.49M -21.10M 29.12M
Total operating expenses 14.40M 1.13M 1.56M 1.22M 1.07M
Cost of revenue 4.30M 2.20M - - 2.97M
Total other income expense net -1.12M -0.54M - -0.66M -0.22M
Net income from continuing ops -1.17M 38.88M 6.81M -22.47M 27.89M
Net income applicable to common shares - - - -22.47M 27.89M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 284.04M 308.15M 304.87M 326.92M 347.83M
Other current assets -15.05M 0.11M - - -
Total liab 34.63M 25.89M 34.55M 42.03M 24.06M
Total stockholder equity 249.41M 282.26M 270.32M 284.89M 323.77M
Other current liab -29.61M -22.83M -0.14M -1.20M -2.19M
Common stock 10.35M 10.35M 10.35M 10.35M 10.35M
Capital stock 10.35M 10.35M 10.35M 10.35M 10.35M
Retained earnings -58.09M -54.03M - -46.66M 252.07M
Other assets 284.04M 308.15M 0.25M 0.15M 0.10M
Cash 14.98M 10.43M - 0.00M 1.56M
Total current liabilities - 1.87M 0.14M 1.20M 2.19M
Net debt 14.63M 12.39M 32.47M 39.98M 20.31M
Short term debt 29.61M 22.83M - - 21.87M
Short long term debt total 29.61M 22.83M 32.47M 39.98M 21.87M
Other stockholder equity 29.87M 294.46M 259.97M 274.54M 313.43M
Total current assets - 10.65M 2.72M 13.34M 2.40M
Long term investments 268.92M 297.51M 301.90M 313.43M 345.34M
Net tangible assets - - - 284.89M 323.77M
Net receivables 0.07M 0.11M 2.72M 13.34M 0.84M
Accounts payable 2.06M 1.87M 0.14M 1.20M 2.19M
Accumulated other comprehensive income 267.28M 31.48M - - -
Non currrent assets other - -297.51M -301.90M -313.43M -345.34M
Non current assets total - 297.51M 301.90M 313.43M 345.34M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Change to liabilities - - - 0.26M 1.48M
Net borrowings 7.76M 24.73M - - -
Total cash from financing activities -23.93M -2.20M -21.39M -16.41M 11.99M
Change to operating activities - - - 19.01M -43.11M
Net income -1.17M 38.88M 6.93M -22.32M 28.05M
Change in cash 4.55M 42.91M 7.50M -19.66M -2.54M
Begin period cash flow 10.43M -32.47M -39.98M -20.31M -17.77M
End period cash flow 14.98M 10.43M -32.47M -39.98M -20.31M
Total cash from operating activities 28.63M 45.35M 27.30M 1.12M -14.53M
Issuance of capital stock - - - 0.00M 23.56M
Other cashflows from investing activities - -50.46M - - -
Dividends paid 11.20M 10.77M 11.41M 12.88M 11.56M
Change to account receivables 0.01M 0.01M - -0.03M -0.78M
Sale purchase of stock -20.49M -16.16M -9.98M -3.53M 23.56M
Change to netincome - - - 4.36M 4.36M
Capital expenditures 28.63M 45.35M 0.00M 0.00M 0.00M
Change in working capital 1.77M -0.73M 22.06M 0.23M -42.42M
Other non cash items 28.03M 7.21M -1.70M 23.22M -0.16M
Free cash flow 28.63M 45.35M 27.30M 1.12M -14.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
IBT
International Biotechnology Trust plc		 5.00
0.49%		 1020.00 - 714.29 16.40 1.20 15.60
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51

Profile*

International Biotechnology Trust plc

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the

31 Gresham Street, London, United Kingdom, EC2V 7QA

44 20 7421 7070

https://www.internationalbiotrust.com

Name Title Year Born
Ms. Lucy Costa Duarte Head of Investor Relations NA
Ms. Catherine Elizabeth Bingham M.B.A. Managing Partner 1966
Ms. Ailsa Craig Investment Mang. NA
Mr. Marek Poszepczynski M Sci Eng Investment Mang. NA
Claire Jackson Company Sec. NA
Dr. Carl Harald Janson Lead Investment Mang. NA
Ms. Catherine Elizabeth Bingham M.B.A. Managing Partner 1967
Ms. Claire Jackson Company Secretary NA
Dr. Carl Harald Janson and CEFA, M.D., Ph.D. Lead Investment Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…